Simultaneous measurement of chemokine/cytokine release and antibody-dependent cellular cytotoxicity upon binding with rituximab

Antibody-dependent cellular cytotoxicity (ADCC) is a cell-mediated immune response where an effector cell destroys an antibody-bound target cell. This process involves cells that express tumor or pathogen-derived antigens on their surface, which are targeted by therapeutic antibodies. The binding of the antibody and the effector cell triggers a series of signaling events, leading to the activation of the effector cell and the release of chemokines and cytokines into the tumor microenvironment.

Simultaneous detection of ADCC activity and release of chemokines and cytokines from activated NK cells is possible via the combined use of DELFIA TRF and AlphaLISA technologies.

Read this application note to access:

• ADCC assay protocol - ADCC experiment with rituximab
• Data collection and analysis
• Formula Calculation and detailed results

For research use only. Not for use in diagnostic procedures.